Friday, December 18, 2015

Ups and downs of a rollercoaster stock market year -- Financial Times

Miners were devastated, but the housebuilders soared

If one of your new year’s resolutions in 2015 was to invest in a FTSE 100 tracker, you may be ruing the day you did so.
With the end of the year nearly upon us, the global resources rout has dragged the index down by more than 7 per cent since January (though an average dividend yield of 4 per cent provides some consolation).
The big question is whether the oil companies and mining stocks that have dug passive investors into a deep hole can climb out of it next year — but few are willing to predict a happy ending in the short term.
The table of the FTSE 100’s biggest losers is dominated by the miners. Topped by Anglo American — down 75 per cent this year as the collapse in the iron ore price caused its dividend payments to cave in — Glencore, BHP Billiton and Antofagasta make up four of the worst five performing stocks, with Rio Tinto languishing at number seven.
Weakening Chinese demand is to blame. It is estimated that there are 100m tons of surplus iron ore in the country as the pace of industrialisation abates — and while low commodity prices persist, analysts fear investors in the sector face further pain from rights issues and restructuring.
Nevertheless, Richard Hunter at Hargreaves Lansdown notes that on measures such as price-to-book and price to cyclically-adjusted earnings, valuations for both the oil companies and the miners are at multi-decade lows. “We may look back in five years and view this as a great buying opportunity,” he says, while cautioning that prices could still have much further to fall.
An interesting point to come out of FT Money’s end-of-year investment review was how fund managers only had to make one call at the start of 2015 to guarantee outperformance — avoiding commodities and miners.
With so many fund managers correctly making this call, to be in the top quartile of UK equity fund managers they would have needed to beat the index by almost 6 percentage points a year on a three-year rolling basis — quite a staggering number.
The other trend to note is the concentration of performance in highly valued growth stocks, and the relative underperformance of everything else (including value stocks, which have underperformed globally for the past five years).
Just look at the table of the FTSE 100 winners, and again, one sector dominates the outperformance — the UK housebuilders. Underpinned by generous government subsidies for new-build homes in the form of Help to Buy and rock-bottom interest rates, Taylor Wimpey is the standout stock, with growth of 46 per cent year-to-date. Barratt and Persimmon also make the top ten.
The chancellor’s continued largesse at the Autumn Statement, with a special Help to Buyproduct for London and promises of thousands of new homes, provided a year-end fillip. But the sting in the tail could be the tougher tax treatment of buy-to-let properties, which face a 3 percentage point surcharge in stamp duty from next April. With overseas investors in new-build homes already facing currency headwinds, higher transaction costs could put them off altogether. And domestically, the Bank of England’s worries about buy-to-let lending could be another party pooper for the builders in 2016.
The narrowing concentration of outperformance is also evident across the pond — the so-called “Fang Nosh” stocks of the S&P 500 (Facebook, Amazon, Netflix, Google plus Nike, O’Reilly Automotive, Starbucks and Home Depot) have been propping up the whole index over there. “Market leadership is becoming progressively narrower, and without these tech and consumer stocks, the index’s performance is far less exciting,” says Gareth Lewis of Tilney Bestinvest.
It is worrying to think how this theme of a “few good winners” could deepen in 2016, and it will be fascinating to watch how the big fund managers diverge in strategy as the year progresses.
But not all passive investors have ended the year on a bum note. If you had decided to track the more domestically focused FTSE 250 at the start of this year, you’d be nearly 7 per cent up — pretty much the opposite of the FTSE 100.
Leaving aside the biggest FTSE 250 winner (Betfair Group, up 143 per cent now competition regulators have approved its merger with rival Paddy Power), the dominant group here are consumer stocks. Rene Ilves

Tuesday, December 8, 2015

Oil benchmark falls below $40 a barrel -- Financial Times

Crude prices drop to lowest level since 2009
Oil prices breached the $40 a barrel mark on Tuesday with internationally traded Brent crude dropping 80 cents to $39.94 a barrel in afternoon trading.
The US benchmark, West Texas Intermediate, declined 91 cents to $36.74 a barrel. Both markers fell to the lowest since February 2009, writes oil and gas correspondent Anjli Raval.
Traders are digesting Friday’s Opec decision to maintain production in the face of lower oil prices after they failed to agree on who should bear the brunt of output cuts.
“Unchanged OPEC policy and the priority of re-gaining a bigger slice of the global oil supply cake is, in fact, bearish and spoils Christmas for oil investors,” said Tamas Varga at London based broker PVM.
“It will be interesting to see how oil price forecasters will adjust their price estimates in the light of the recent developments.”
Traders are increasingly bearish on oil prices and this is reflected in their short positions.
The ‘lower for longer’ mantra has become embedded in the oil industry lexicon with observers struggling to find reasons to have a positive view on the oil price in the near term.
“Money managers holding a record short position in the futures market have so far seen no reason to scale back positions,” Ole Hansen at Saxo Bank. “Until there’s a change in the outlook, which looks horrible, the upside potential seems limited.”

Tuesday, November 24, 2015

Political risk clouds Pfizer-Allergan deal

Investors and analysts see the transaction as vulnerable to a change in ‘tax inversion’ law

Pfizer and Allergan would have to pay the other party just $400m if either one were to pull out of their $160bn deal due to a possible change in the law. For such a large transaction, it would be a tiny break-up fee and one that threatens to fuel concerns the combination could fall through.
The termination fee for pulling out of the deal for other reasons would stand between $3bn and $3.5bn, in line with other deals of this size, but the merger agreement allows the companies to walk away for a fraction of that amount “due to an adverse change in the law”.
Analysts and investors said there was nervousness that the largest ever “inversion” deal could fall prey to political interference, because it would allow Pfizer to avoid at least $21bn in future US tax bills by moving the combined group to Ireland, where Allergan is based.
In a note to investors, analysts at Evercore ISI said the $400m break-up fee signalled a “lack in absolute confidence that the US Treasury could not force a change in regulations prior to the close of the transaction that would negatively impact the deal”.
The merger agreement was published as Pfizer kicked off a round of meetings with top shareholders on Tuesday to garner support for the biggest tax inversion in history, as market reaction suggested investors were pricing in a significant chance of the transaction collapsing.
Shares in Dublin-based Allergan were trading at $303 during early New York trading on Tuesday, roughly 19 per cent below Pfizer’s all-stock offer, which was worth about $362 per share — a large discount given that both boards have signed off on the friendly deal.
There was a chorus of opposition from Democrat politicians when the deal was announced on Monday, and from Donald Trump, the Republican presidential nominee, who said “the fact that Pfizer is leaving our country with a tremendous loss of jobs is disgusting”.

Pfizer has not said how many jobs will be lost following the merger, but it expects to cut costs by $2bn over three years.
There is also discontent among large Allergan investors, some of whom believe the company is being sold on the cheap and is worth at least $400-a-share or more, prompting concerns that they could oppose the transaction or hold out for a better offer from Pfizer.
Pfizer’s move to delay a decision on whether to break itself into two — with one company focused on branded drugs and another on older medicines — also disappointed some investors, who had hoped the Allergan takeover would hasten a split.
“There some concern around the Federal government trying to block the deal — people are just not reassured,” said Ronny Gal, an analyst at Bernstein. “There is also a secondary concern that investors in Allergan, who are unhappy with the price, will revolt against the deal.”
The long timeline for completing the deal, which will not be consummated until the latter half of next year, is adding to nervousness, according to one sizeable Allergan investor. Pfizer’s decision to ditch its last attempt at an inversion — the £69.4bn takeover of Britain’s AstraZeneca — in the face of political opposition was also a concern, the investor said.
Ian Read, Pfizer’s chief executive, started meeting top investors in both companies on Tuesday, according to people familiar with the situation, to try to soothe nerves and make the case for the strategic benefits of the deal. A Pfizer spokesperson confirmed Mr Read was meeting shareholders.
“In the case of AstraZeneca, the company didn’t have the support of the target’s management or board, or the British government,” said an adviser to Mr Read. “Whereas this time round, the Allergan executives are on board, the Irish government hasn’t opposed it, and the US administration has admitted there is very little they can do.”

Some analysts believe that Pfizer and Allergan purposely underplayed some of the financial benefits of the deal, such as the potential for cost cutting, and refrained from offering details of what are expected to be huge shareholder buybacks, to avoid fuelling political opposition.
Cost savings in excess of the $2bn-over-three-years target outlined on Monday could stoke fears of significant job losses, according to analysts. Meanwhile, using Pfizer’s foreign cash reserves to fund shareholder returns rather than spending on research and development would undermine the company’s claim that the deal will be good for American science.
“We believe Pfizer and Allergan are strongly incentivised to understate potential tax, operating expenditure [savings], and earnings accretion given the heavy political scrutiny underpinning the planned inversion out of the US,” said Andrew Baum, an analyst at Citi.
However, it could be difficult for Pfizer to offer investors more bullish forecasts in private because of Irish takeover rules that require companies to make relevant information publicly available to all shareholders.
A person close to Mr Read said he was prepared for the chorus of political opposition and that he was relaxed about the market reaction.
“You announce a big deal, it doesn’t close for a while, it isn’t accretive in the first year, and it puts off your separation — it’s not a message that’s going to have the stock up 5 per cent,” the person said.

Financial Times
-----------------------------
Rene Ilves

Tuesday, November 17, 2015

Merko

Olen natuke internetis ringi kaevanud ja silma on jäänud paar tähelepanuväärset infokildu.

- E.L.L. Kinnisvara alustab Vilniuses 5100m2 kontorihoone ehitusega. Maksumus ca 9 MEUR.
http://ell-realestate.com/uudised/uue-buroohoone-narbuto-5-ehitus-sai-rohelise-tule/

- E.L.L. KV plaanib lähiajal alustada Riias Spice keskuse laiendamist 10 000m2 võrra. Hinnanguline suurusjärk on 15-20MEUR
http://ell-realestate.com/uudised/e-l-l-kinnisvara-ostis-olumpia-hotelli-vastas-paiknevad-kinnistud/

- Samuti plaanitakse laiendada Spice Home projekti, mis OberHausi hinnangul on 60MEUR projekt.
http://www.ober-haus.ee/en/research/3615-2/

- E.L.L. KV plaanib Riiga ehitada kaks kontorihoonet kogupinnaga 23 000m2. Hinnanguline maksumus 40-50MEUR
http://ell-realestate.com/uudised/e-l-l-kinnisvara-ostis-olumpia-hotelli-vastas-paiknevad-kinnistud/

- E.L.L. ostis hiljuti Liivalaia/Juhkentali krundi, millele kerkib mitu suurt hoonet.
http://tallinncity.postimees.ee/3381007/olumpia-hotelli-naaberkrundile-kerkib-lahiaastatel-kuni-30-korruseline-arihoone

Üpris suure tõenäosusega ehitab kõik need Merko.

Tuesday, November 10, 2015

Chinese billionaire buys Modigliani nude for $170m at Christie’s

The billionaire founder of a Shanghai museum paid $170.4m for an Amedeo Modigliani nude at Christie’s in New York on Monday, carrying a night in which global art buyers focused their attention on a few masterworks but left other lots unsold.
The Italian painter’s “Nu Couché (Reclining Nude)” went under auctioneer Jussi Pylkkanen’s hammer for $152m before fees, marking the second-highest price for a work sold at auction and far exceeding the estimate of about $100m.

Thursday, November 5, 2015

Rene Ilves: Merko on valesti hinnatud

Merko Ehituse investor Rene Ilves usub, et rahatrükk ei ole ehitusfirmale veel mõju avaldanud ning et ettevõte on valesti hinnatud.
„Tulemused vastasid analüütikute ootustele. QE (kvantitatiivne leevendamine – toim) ja eurorahad ei ole veel mõjuma hakanud, nende mõju peaks saabuma järgmisel aastal,“ ütles Ilves. „Usun endiselt, et ettevõte on valesti hinnatud ja hoian aktsiaid edasi.“
Rene Ilves ütles selle aasta alguses, et Euroopa Keskpanga rahatrükk võib selle aasta lõpuks Tallinna börsi 50% ülespoole vedada ja kõige suuremat kasu lõikaks sellest Merko Ehituse aktsia.
Merko Ehitus teatas täna, et kontserni müügitulu oli kolmandas kvartalis 68,4 miljonit eurot ja puhaskasum 3,1 miljonit eurot. Merko aktsia oli kella 13 tõusnud ligi pool protsenti, 7,78 euroni.
Rene Ilvesele kuulub ettevõtte Seitse Samuraid OÜ kaudu 61 500 Merko aktsiat.

Wednesday, November 4, 2015

Michael Kors profit and revenue beats estimates, shares surge

Michael Kors Holding Ltd. KORS, +0.92% said Wednesday it had net income of $193.1 million, or $1.01 a share, in its fiscal second quarter, compared with $207 million, or $1.00 a share, in the year-earlier period. Revenue rose 6.9% to $1.13 billion. The FactSet consensus was for EPS of 90 cents and revenue of $1.075 billion. "We drove growth in our retail and wholesale segments as well as across our operating regions in the Americas, Europe and Japan," Chief Executive John Idol said in a statement. Looking ahead, the company is expecting third-quarter revenue to range from $1.33 billion to $1.35 billion, compared with the current FactSet consensus of $1.39 billion. EPS is expected to range from $1.44 to $1.48, compared with the FactSet consensus of $1.53. The board approved an additional share buyback of $500 million. Shares surged 9% in premarket trade, but are down 47% in the year through Tuesday, while the S&P 500 has gained 2.5%.

http://www.marketwatch.com/story/michael-kors-profit-and-revenue-beats-estimates-shares-surge-2015-11-04?siteid=bulletrss

Tuesday, November 3, 2015

Crude oil recovers off lows but glut keeps lid on gains

Oil recovered off earlier lows on Tuesday, but stayed well below $50, pressured by a glut in supply and worries about a fragile demand outlook.
Brent crude futures LCOc1 were up 33 cents at $49.12 by 1100 GMT, but gains were kept in check by Russian production hitting a post-Soviet peak and a weaker outlook for demand from China.
U.S. crude futures CLc1 were up 39 cents $46.53 per barrel, after falling in the previous session due to a rise in stockpiles.

"It's all about supply," said Michael Hewson, analyst at CMC Markets. "Oil's going to remain under pressure, with inventories likely to expand and the potential for Iranian supply to come on stream in the next few months."

Monday, November 2, 2015

Record levels of cash flocking to the U.S.

A record breaking amount of cash is flocking to the United States.


Foreign direct investment into the U.S. hit $200 billion in the first half of 2015, a record high according to a report published Thursday by the Organization for Economic Cooperation and Development (OECD).
It's a sign that global investors are optimistic about the U.S. economyat a time when the rest of the global economy undergoes a slowdown.
However, a lot of the money can be traced to foreign entities that are buying U.S. companies. Many of these companies then relocate overseas to escape high corporate taxes in the United States.
"These flows were driven not just by the improved economic performance in the United States but also by cross-border M&A designed to reduce companies' U.S. tax obligations," the OECD said in its report.
About $86 billion of the $200 billion went towards chemical companies. Another $80 billion to manufacturing companies. The OECD surmises that most of these funded mergers.

Rene Ilves: Thank God for QE!

Friday, October 30, 2015

Valeant severs ties with controversial pharmacy distributor

Valeant Pharmaceuticals International (VRX.TO) is to sever all ties with pharmacy business Philidor Rx Services in the wake of criticism over the relationship between the two closely associated companies.

Valeant and Philidor, which has helped to drive sales for the Canadian drugmaker, have come under fire after influential short-seller Citron Research said Philidor was being used to create "phantom accounts" and inflate Valeant's revenue. Valeant has denied any wrongdoing.

Rene Ilves: hehee, Ackman just jõudis valmis teha presentatsiooni: "Philidor veri guud."

Thursday, October 29, 2015

Valeant's ambitious plan for its contact lens business

Valeant Pharmaceuticals International has pursued a plan in recent months to dominate the market for specialty contact lenses, according to two people familiar with the company’s approach and some of the company’s communications with its customers.

The Canadian drugmaker's goal, spelled out to key employees and demonstrated through its actions, has been to acquire other manufacturers, take on competitors and raise prices for unfinished lens components.

Antud sektoris on ka teisi firmasid, mis võivad pihta saada kui hakatakse uurima kontaktläätse äri. Rene Ilves

Wednesday, October 28, 2015

Rene Ilves: harv ausus Tallinna börsil

Järvevana suuruselt teise aktsionäri Rene Ilvese sõnul oli börsifirma suurosaniku Toomas Annuse otsus osta kõik ettevõtte aktsiad ootuspärane.

http://www.aripaev.ee/uudised/2014/08/01/rene-ilves-annuse-otsus-on-harv-ausus-tallinna-borsil

Rene Ilves: Olympicul trumbid varuks

Olympic Entertainment Groupi väikeaktsionär Rene Ilves märkis ettevõtte värskeid majandustulemusi kommenteerides, et hoolimata neljanda kvartali puhaskasumi langusest võib kasiinofirmal varrukas nii mõnigi trump varuks olla.

http://www.aripaev.ee/borsiuudised/2015/02/26/rene-ilves-olympicul-trumbid-varuks

Rene Ilves: ei imesta, kui Tallinna börs tõuseks 50%



Väikeinvestor Rene Ilves usub, et Euroopa Keskpanga rahatrükk võib aasta lõpuks Tallinna börsi 50% ülespoole vedada ja kõige suuremat kasu lõikaks sellest Merko Ehituse aktsia.

http://www.aripaev.ee/borsiuudised/2015/02/09/rene-ilves-ei-imestaks-kui-tallinna-bors-touseks-50